First-in-human phase 1b study of ATRC-101, a patient-derived antibody with a tumor-specific target, as monotherapy or in combination with pembrolizumab, in patients with solid tumors. Benjamin, J. E., Higgins, N., Millward, C., DeFalco, J., Manning-Bog, A., Aydin, I. T., Zhang, D., Lippow, S. M., Scholz, A., Leung, Y., Zhu, Y., Sedello, A., Rogers, Z., Dhawan, I. K., Emerling, D., Robinson, W. H., Serafini, T. A., Greenberg, N. M. AMER ASSOC CANCER RESEARCH. 2021

View details for Web of Science ID 000680263501286